1st IPOPI
National Patient Organisations Survey

January 2011
The 1st IPOPI National Member Organisation (NMO) Survey was initiated (Feb-Aug 2010) to establish a mapping of the following criteria amongst IPOPI’s NMO’s:

- Estimated Number of patients in each country
- Number of known diagnosed PID cases
- Patient demographics
- Presence of national registries & potential collaborations with international registries
- Provision of care, availability of treatment and funding of care in each country
- National Medical Advisory Panels
- Communication tools
Survey Background

• IPOPI NMO Survey
  – Mixed mode, internet & paper
  – February – August 2010
  – NMOs allowed to resubmit updated data
  – Concerted effort to collect data from non-respondents
    • Included submissions of “off-line” surveys

• 33 NMO’s represented
  – Substantial completion of 32 surveys
## Survey Participants

<table>
<thead>
<tr>
<th>Countries Represented</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>Germany</td>
<td>Norway</td>
</tr>
<tr>
<td>Australia</td>
<td>Greece</td>
<td>Poland</td>
</tr>
<tr>
<td>Austria</td>
<td>Hungary</td>
<td>Russia</td>
</tr>
<tr>
<td>Belgium</td>
<td>Iceland</td>
<td>Serbia</td>
</tr>
<tr>
<td>Brasil</td>
<td>India</td>
<td>South Africa</td>
</tr>
<tr>
<td>Canada</td>
<td>Ireland</td>
<td>Spain</td>
</tr>
<tr>
<td>Colombia</td>
<td>Italy</td>
<td>Sweden</td>
</tr>
<tr>
<td>Cyprus</td>
<td>Japan</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Denmark</td>
<td>Morocco</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Estonia</td>
<td>Netherlands</td>
<td>United States</td>
</tr>
<tr>
<td>France</td>
<td>New Zealand</td>
<td>Venezuela</td>
</tr>
</tbody>
</table>
Knowledge of Number of PID Cases in Country

The knowledge of diagnosed PID patients is uneven and varies from country to country. Half of IPOPI’s national member organisations know how many patients have been diagnosed in their country.
Number of NMO Patient Members

Mean = 770   Median = 98

Representing 22,332 Patients

This is the range of the reported numbers of patients who are actually members of IPOPI’s NMOs. The smallest NMO’s do not yet have members either because they have just started or halted their activities.
Q3a. How many patients with a PID diagnosis are members of your NMO in total? Base: Those responding (N =29)
Countries with highest numbers of reported PID patients, members of their NMO’s, per million population were Sweden, Canada, USA, NZ and UK.
Actual Reported Number of Patient Members per million population (>10 and < 30)
Actual Reported Number of Patient Members per million population (>10 and < 30)
IPOPI national member organisations provided the number of estimated of PID patients in their countries. It is important to note that in some cases these are actually counts of patients in a registry, in others they are estimations based on surveys, or based on estimates of population prevalence gathered from peer reviewed journal publications and extrapolated to the national population.
Estimated PID Cases Grouped by Selected Ranges

<table>
<thead>
<tr>
<th>Reported Number of Diagnosed Patients</th>
<th>Number of NMOs</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 - 259</td>
<td>6</td>
</tr>
<tr>
<td>400 - 800</td>
<td>7</td>
</tr>
<tr>
<td>1,300 - 1,519</td>
<td>3</td>
</tr>
<tr>
<td>2,000 - 3,260</td>
<td>5</td>
</tr>
<tr>
<td>6,000 - 7,000</td>
<td>3</td>
</tr>
<tr>
<td>250,000</td>
<td>1</td>
</tr>
</tbody>
</table>
Estimated PID cases per million population (>100 and < 1000)

Countries with highest numbers of estimated PID patients per million population were Cyprus, USA, Australia, Belgium and Sweden.
Estimated PID cases per million population (>40 and < 130)
Estimated PID cases per million population (< 40)

These are the countries with lowest numbers of estimated PID patients per million population.
In conclusion, establishing prevalence rates remain very difficult as different calculation modes, different opinions and different diagnosis rates are used from country to country.

IPOPI’s recommendation would be to define a worldwide prevalence rate for PID.
The majority of IPOPI NMOs have a good knowledge of the proportion of adults and children within their membership.
Demographics of Known Patients (Age)

Number Pediatric (0 – 17 years)

- **Range**: 2
- Mean = 430
- Median = 70

Number Adult (18+ years)

- **Range**: 0
- Mean = 661
- Median = 60
Knowledge of Patient Demographics (Diagnosis)

Two third of IPOPI NMOs were able to break down their membership numbers by diagnosis.
Common variable immunodeficiency (CVID) is the most frequent diagnosis reported by IPOPI's members. Importantly, other more severe forms, such as SCID where mortality rates are higher, are not always known or reported in these figures.
Approximately half of IPOPI members report having a national registry in their country.
Number of Patients in National Registries

The range of actual patients registered in a national registry varies from country to country. In total 17,553 are registered in these registries.
NMO Participation In International PID Registries

- Number of reported national registries participating in international registries such as ESID. Other international registries included ASCIA and LASID. This highlights that whilst international registry cooperation is happening much remains to be done.

IPOPI encourages the harmonization and compatibility of registries to facilitate international cooperation.
The majority of IPOPI’s NMOs reported that adult care and treatment were available in their country. 9% reported this was not the case in their country. 6% reported that adult care was available but with limitations.
Provision of Care for Adult Patients With PID – Country Spilt

[Map showing countries colored by provision of care: green for Yes, orange for Some, red for No]
IVIG is reported as the most widely available type of treatment in all surveyed countries. SCIG is reported to be available in 72% of countries. In addition, 13% of countries report having access to SCIG under special circumstances (e.g., clinical trials).
Availability of Treatment for Patients*

- IVIG / SCIG / BMT-SCT / Other
- IVIG / SCIG / BMT-SCT / Other (Morocco)
- IVIG / BMT-SCT (Serbia)
- IVIG / SCIG / Other (Ireland)
- IVIG (India, Estonia)

* Includes SCIG under special circumstances (i.e.: clinical trials)
47% of IPOPI’s NMOs indicated that patients in their country do have to pay for some portion of their treatment. In some countries this includes paying for their IG therapies, in others only for a portion or for treatments such as antibiotics or for the day of hospitalization.
How Patient Treatments are Paid

The most reported type of treatment coverage is through government health plans and private health plans. Still 6% of NMO’s report that their patients have to cover the costs of treatment themselves.
How Patient Treatments are Paid

Government Health Plan
Patient only
Government & Patient Insurance
Government & Private Insurance
Private Insurance
Government, Patient & Private Insurance
NMOs With Medical Advisory Committee

78% of IPOPI’s NMOs have a Medical Advisory Panel

IPOPI strongly encourages all of its NMOs to establish a Medical Advisory Panel. The mission of the MAP is to provide guidance on all matters concerned with the medical care of people living with a PID.
To ensure an efficient and consistent national strategy, IPOPI strongly encourages the presence of only one NMO per country. Should regional representation be absolutely needed chapters reporting to an overarching national organisation could be envisaged.
Half of IPOPI’s NMO’s report publishing a printed newsletter.
These newsletters are published between 1 to 5 times per year.
Only 28% of IPOPI's NMOs report publishing an electronic newsletter.
These electronic newsletters are published between 1 to 13 times per year.
87% of IPOPI’s NMO’s report having an active website
# Conclusions

<table>
<thead>
<tr>
<th>Good to know....</th>
<th>...areas for improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Better estimate of how many patients and diagnosed patients per country</td>
<td>Gap between estimated number of patients and actual diagnosed cases</td>
</tr>
<tr>
<td>Demographics: good overall picture adult/paediatric patients and spilt per condition</td>
<td>Condition split figures to be improved (1/3 missing)</td>
</tr>
<tr>
<td>Presence of registries in 50% of countries</td>
<td>Presence of registries in 50% of countries</td>
</tr>
<tr>
<td></td>
<td>Collaboration between national and international registries in 30% of cases</td>
</tr>
<tr>
<td>Overall good access to care for diagnoses patients</td>
<td>What about undiagnosed patients?</td>
</tr>
<tr>
<td>Overall good coverage through national health insurance plans</td>
<td>Still countries with no government coverage</td>
</tr>
</tbody>
</table>
## Conclusions

<table>
<thead>
<tr>
<th>Good to know....</th>
<th>...areas for improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most NMO’s have established a Medical Advisory Panel (MAP)</td>
<td>Minority without a MAP</td>
</tr>
<tr>
<td>Communication tools:</td>
<td>Communication tools:</td>
</tr>
<tr>
<td>Large majority of NMO’s do have a website</td>
<td>Minority with no website</td>
</tr>
<tr>
<td>50% NMO’s do not have a printed newsletter and 72% do not have an e-newsletter</td>
<td></td>
</tr>
</tbody>
</table>
Conclusions

• Encouraging participation from IPOPI NMO’s

• Good first overview on number of patients, demographics, provision of care, presence of registries and communication tools

• IPOPI intends to conduct more surveys in the future to build a database of key information. This will strengthen IPOPI’s advocacy efforts to promote access to care and early diagnosis on behalf of PID patients worldwide